Varsal is a specialty chemical company that develops and supplies pharmaceutical intermediates and specialty chemicals for the pharmaceutical, electronics, and industrial markets. The company's primary products are complex chemical building blocks used by drug manufacturers to produce active pharmaceutical ingredients. Key offerings include toluenesulfonylmethyl isocyanide, triflic acid, and various sulfonyl and phosphorous chemicals. Varsal uses a capital-light business model and does not own manufacturing facilities. Instead, Varsal develops proprietary chemical processes and directs a network of five third-party manufacturers in China to produce goods to its specifications. Varsal then manages global logistics, quality control, and delivery for its customers. This model allows Varsal to maintain a lean staff of ten employees while focusing on process optimization to reduce costs. The company's products create high switching costs because they are custom-designed for specific regulatory requirements. Substituting a qualified supplier in pharmaceutical manufacturing requires lengthy regulatory approvals, which discourages customers from changing vendors. Varsal relies on a highly concentrated customer base, with a single pharmaceutical company recently accounting for the majority of revenue. The company's growth strategy focuses on acquiring manufacturing sites in the U.S. to reduce tariff exposure and establishing a production facility in Saudi Arabia to leverage low-cost raw materials.